• If you are wondering whether Humana's share price now reflects fair value or if the market has swung too far, you are not alone. This article aims to unpack that question clearly.
• Humana's stock has faced heavy pressure recently, with the price at US$176.06 after a 5.9% decline over the last 7 days, 33.2% over the last month and 33.4% year to date. This has contributed to a 30.0% 1-year return and 63.3% and 51.8% returns over 3 and 5 years respectively.
• Recent coverage around Humana has focused on its shifting position within the US healthcare sector. This includes commentary on how policy changes, competitive pressures and cost trends may be affecting investor sentiment. These themes help explain why the market has been reassessing the share price and provide useful context for any valuation work.
• Against that backdrop, Humana earns a valuation score of 5/6 on our checks. This raises important questions about how its current price stacks up against different valuation methods. We will walk through those methods and then finish with a broader way to think about what valuation really means for you as a shareholder.

Approach 1: Humana Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and discounting them back to a present value. It is essentially asking what all those future dollars are worth in today's terms.

For Humana, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is reported at about US$142.2m. Analysts provide explicit free cash flow estimates out to 2030, with projected free cash flow of US$4.9b in that year. Beyond the first few years, Simply Wall St extrapolates additional free cash flow figures out to 2035 using its own growth assumptions and then discounts each year back to today.

Adding these discounted cash flows together produces an estimated intrinsic value of about US$1,013.42 per share. Compared with the current share price of US$176.06, the model implies an intrinsic discount of roughly 82.6%. This suggests that the shares are trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Humana is undervalued by 82.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Humana Price vs Earnings

For a profitable company, the P/E ratio is a useful way to relate what you are paying for each share to the earnings that business is currently generating. It gives you a quick sense of how many dollars investors are willing to pay today for one dollar of earnings.

What counts as a "normal" P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower expected growth or higher risk usually points to a lower P/E being reasonable.

Humana currently trades on a P/E of 17.87x. This sits below the Healthcare industry average of 23.61x and the peer group average of 20.94x. Simply Wall St also calculates a proprietary Fair Ratio for Humana of 34.82x, which reflects factors such as earnings growth, profit margins, industry, market cap and key risks. This Fair Ratio aims to be more tailored than a simple comparison with peers or the broad industry, because it adjusts for the specific profile of the company you are looking at.

Comparing Humana’s current 17.87x P/E with the 34.82x Fair Ratio indicates the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.

Upgrade Your Decision Making: Choose your Humana Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple framework on Simply Wall St's Community page that lets you connect your view of Humana’s story to specific forecasts for revenue, earnings and margins, which then roll up into your own fair value that you can compare with today’s price.

You can think of a Narrative as the explanation behind the numbers, where you spell out why you think Medicare Advantage regulation, cost trends and Humana’s execution will play out a certain way, then link that story to assumptions like a fair value of US$146.00 at the cautious end or US$348.00 at the optimistic end.

Because Narratives on the platform are refreshed as new earnings, regulatory news or guidance arrive, you can quickly see when your fair value view drifts away from the current share price and decide for yourself whether the updated gap between price and value still fits the story you believe in.

For Humana however, here are previews of two leading Humana Narratives:

Fair value: US$212.87

Implied discount to this fair value: 17.3%

Revenue growth assumption: 8.70%

• Regulators are tightening oversight of Medicare Advantage, with closer scrutiny of risk adjustment data, prior authorizations and medical necessity.
• For Humana, data quality, documentation and clinical justification are central to managing audit risk and potential repayment obligations.
• Insurers that invest early in stronger internal controls and compliance processes may be better placed as Medicare Advantage moves into a more disciplined era.

Fair value: US$146.00

Implied premium to this fair value: 20.6%

Revenue growth assumption: 9.10%

• Heavy reliance on Medicare Advantage leaves Humana exposed to policy shifts, reimbursement changes and political reform debates.
• Rising medical costs, higher utilization and new tech driven competitors could pressure margins if cost efficiencies fall short.
• Bearish analysts anchor on a lower fair value that assumes modest revenue growth, tight margins and a reduced future P/E multiple compared with the broader US Healthcare sector.

If you want to see how other investors are balancing these types of narratives with their own assumptions on growth, margins and regulation, Curious how numbers become stories that shape markets? Explore Community Narratives can be a useful next step.

Do you think there's more to the story for Humana? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.